EMMPRIN is an independent negative prognostic factor for patients with astrocytic glioma.
Extracellular matrix metalloproteinase inducer (EMMPRIN), also known as CD147, is a member of the immunoglobulin superfamily that is present on the surface of tumor cells and stimulates adjacent fibroblasts to produce matrix metalloproteinases (MMPs). It has been proved to be associated with tumor i...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3596336?pdf=render |
id |
doaj-8639f302a9aa4e0292ad67df3dc6894e |
---|---|
record_format |
Article |
spelling |
doaj-8639f302a9aa4e0292ad67df3dc6894e2020-11-25T01:00:10ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0183e5806910.1371/journal.pone.0058069EMMPRIN is an independent negative prognostic factor for patients with astrocytic glioma.Li TianYang ZhangYu ChenMin CaiHailong DongLize XiongExtracellular matrix metalloproteinase inducer (EMMPRIN), also known as CD147, is a member of the immunoglobulin superfamily that is present on the surface of tumor cells and stimulates adjacent fibroblasts to produce matrix metalloproteinases (MMPs). It has been proved to be associated with tumor invasion and metastasis in various human malignancies. In our study, the protein expression level of EMMPRIN in 306 cases of astrocytic glioma is investigated by immunohistochemistry assay. Statistical analysis was utilized to evaluate the association of EMMPRIN with clinicopathological characteristics and prognosis of patients. It was proved that EMMPRIN protein expression was increased in glioma compared with that in normal brain tissue. Moreover, EMMPRIN immunohistochemical staining was correlated with WHO grade and Karnofsky performance score for strong positive EMMPRIN staining is more frequently detected in glioma of advanced grade or low KPS score. It is also demonstrated that EMMPRIN could be an independent negative prognostic factor in glioma for patients with glioma of strong EMMPRIN staining tend to have high risk of death. These results proved that EMMPRIN is associated with prognosis of glioma, which may also suggest the potential role of EMMPRIN in glioma management.http://europepmc.org/articles/PMC3596336?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Li Tian Yang Zhang Yu Chen Min Cai Hailong Dong Lize Xiong |
spellingShingle |
Li Tian Yang Zhang Yu Chen Min Cai Hailong Dong Lize Xiong EMMPRIN is an independent negative prognostic factor for patients with astrocytic glioma. PLoS ONE |
author_facet |
Li Tian Yang Zhang Yu Chen Min Cai Hailong Dong Lize Xiong |
author_sort |
Li Tian |
title |
EMMPRIN is an independent negative prognostic factor for patients with astrocytic glioma. |
title_short |
EMMPRIN is an independent negative prognostic factor for patients with astrocytic glioma. |
title_full |
EMMPRIN is an independent negative prognostic factor for patients with astrocytic glioma. |
title_fullStr |
EMMPRIN is an independent negative prognostic factor for patients with astrocytic glioma. |
title_full_unstemmed |
EMMPRIN is an independent negative prognostic factor for patients with astrocytic glioma. |
title_sort |
emmprin is an independent negative prognostic factor for patients with astrocytic glioma. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
Extracellular matrix metalloproteinase inducer (EMMPRIN), also known as CD147, is a member of the immunoglobulin superfamily that is present on the surface of tumor cells and stimulates adjacent fibroblasts to produce matrix metalloproteinases (MMPs). It has been proved to be associated with tumor invasion and metastasis in various human malignancies. In our study, the protein expression level of EMMPRIN in 306 cases of astrocytic glioma is investigated by immunohistochemistry assay. Statistical analysis was utilized to evaluate the association of EMMPRIN with clinicopathological characteristics and prognosis of patients. It was proved that EMMPRIN protein expression was increased in glioma compared with that in normal brain tissue. Moreover, EMMPRIN immunohistochemical staining was correlated with WHO grade and Karnofsky performance score for strong positive EMMPRIN staining is more frequently detected in glioma of advanced grade or low KPS score. It is also demonstrated that EMMPRIN could be an independent negative prognostic factor in glioma for patients with glioma of strong EMMPRIN staining tend to have high risk of death. These results proved that EMMPRIN is associated with prognosis of glioma, which may also suggest the potential role of EMMPRIN in glioma management. |
url |
http://europepmc.org/articles/PMC3596336?pdf=render |
work_keys_str_mv |
AT litian emmprinisanindependentnegativeprognosticfactorforpatientswithastrocyticglioma AT yangzhang emmprinisanindependentnegativeprognosticfactorforpatientswithastrocyticglioma AT yuchen emmprinisanindependentnegativeprognosticfactorforpatientswithastrocyticglioma AT mincai emmprinisanindependentnegativeprognosticfactorforpatientswithastrocyticglioma AT hailongdong emmprinisanindependentnegativeprognosticfactorforpatientswithastrocyticglioma AT lizexiong emmprinisanindependentnegativeprognosticfactorforpatientswithastrocyticglioma |
_version_ |
1725214847010865152 |